Eleven analysts currently cover Encompass Health, with eight assigning a buy rating, two a strong-buy and one a hold. The group’s average 12-month price target sits at $142.86, implying roughly 20% upside from recent trading levels. Raymond James upgraded to strong-buy on October 31, while Barclays raised its target from $141 to $150 and maintained an overweight view. KeyCorp recently lifted its target from $135 to $140, underscoring improving confidence in the company’s growth trajectory and cash-flow generation.

Encompass Health will report results for the quarter ended December 31 after the market closes on Thursday, February 5, followed by an investor conference call at 10:00 a.m. ET on Friday, February 6 (dial-in: 800-267-6316 or 203-518-9783, conference ID EHCQ425). The webcast and replay will be available on the company’s investor website. Investors will focus on same-facility rehabilitation admissions growth, margin trends in inpatient hospitals and home health services, and updates to full‐year guidance for 2026.

In the March quarter, Encompass Health delivered $0.93 earnings per share on $136.3 million of revenue, translating to a 9.33% net margin and a 17.84% return on equity. Analysts forecast full-year EPS of 4.8, reflecting steady organic volume gains and disciplined cost control. The company carries a debt-to-equity ratio of 0.76 and maintains a current and quick ratio of 1.14, supporting investment in technology and facility expansion. With a market capitalization near $10.4 billion, a P/E of 19.5, a P/E/G of 1.69 and a beta of 0.74, Encompass Health trades in line with peers while offering a modest dividend yield of 0.7% and a 14.4% payout ratio.